Completed NA INTERVENTIONAL 2-arm NCT00421018

Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)

Optimization of the Anti-Inflammatory Treatment of Asthma Patients Through Exhaled NO Measurements for Increased Asthma-Related Quality of Life in Primary Health Care (NOAK)

Sponsor: Aerocrine AB

Conditions Allergic Asthma

Interventions Single corticosteroid inhalers and Singulair

Updated 8 times since 2017 Last updated: Aug 14, 2012 Started: Nov 30, 2006 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Allergic Asthma, this trial is completed. The trial is conducted by Aerocrine AB and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Oct 2021 — Jun 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Jan 2021 — Oct 2021 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aerocrine AB
Karolinska Institutet
Meda AB
Merck Sharp & Dohme LLC
Phadia AB
Region Stockholm
Swedish Council for Working Life and Social Research
The Swedish Research Council
Uppsala University

Data source: Karolinska Institutet

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Upplands Vasby, Sweden